RGLS Regulus Therapeutics Inc Recent Headline News
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - 2 hrs 28 mins ago
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.49 (+1.04), ACHN: 12.54 (+2.43), RGLS: 23.00 (+0.92), ABBV: 63.60 (+2.10)
Regulus Therapeutics (RGLS) Strong On High Relative Volume Today
at The Street - Mon Nov 10, 9:04AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 23.00 (+0.92)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 325.03 (+4.28), ALNY: 98.77 (+2.93), ISIS: 46.24 (+1.65), OGXI: 2.15 (-0.03), TEVA: 58.03 (+0.33), RGLS: 23.00 (+0.92), GSK: 45.17 (+0.26), SNY: 46.24 (+0.55)
Regulus to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. The conference is being held at the Arizona Biltmore in Phoenix, AZ.
RGLS: 23.00 (+0.92)
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 31.84 (-0.04), RGLS: 23.00 (+0.92), WAB: 89.47 (+0.20)
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next?